Cue Biopharma Inc CUE:NASDAQ

Last Price$3.75NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/17/22

Today's Change+0.13(3.59%)
Bid (Size)$3.50 (20)
Ask (Size)$4.19 (7)
Day Low / High$3.59 - 3.86
Volume186.1 K

View Biotechnology IndustryPeer Comparison as of 05/17/2022


Cue Biopharma Inc ( NASDAQ )

Price: $3.75
Change: +0.13 (3.59%)
Volume: 186.1 K
4:00PM ET 5/17/2022

INmune Bio Inc ( NASDAQ )

Price: $7.49
Change: +0.33 (4.61%)
Volume: 101.5 K
4:00PM ET 5/17/2022


Price: $3.27
Change: +0.35 (11.99%)
Volume: 864.4 K
8:00PM ET 5/17/2022

ContraFect Corp ( NASDAQ )

Price: $3.35
Change: +0.15 (4.69%)
Volume: 74.6 K
4:00PM ET 5/17/2022

Pieris Pharmaceuticals Inc ( NASDAQ )

Price: $1.82
Change: +0.13 (7.69%)
Volume: 448.5 K
4:00PM ET 5/17/2022

Read more news Recent News

Cue Biopharma Says FDA Approves Investigational New Drug Application for Early Trial of Cancer Treatment CUE-102
9:47AM ET 5/11/2022 MT Newswires

Cue Biopharma (CUE) said Wednesday the Food and Drug Administration has approved its investigational new drug application for a phase 1 trial of CUE-102 to...

Cue Biopharma Shares Rise After Insider Buy
12:53PM ET 4/05/2022 MT Newswires

Cue Biopharma (CUE) shares were up 4.6% in Tuesday afternoon trading after insider activity from its management and a director on March 31. The...

Insider Buy: Cue Biopharma
5:31PM ET 4/04/2022 MT Newswires

Aaron G.L. Fletcher, Director, on March 31, 2022, executed a purchase for 735,000 shares in Cue Biopharma (CUE) for $3,498,600. Following the Form 4 filing...

JMP Securities Adjusts Cue Biopharma's Price Target to $15 From $30, Maintains Market Outperform Rating
6:38AM ET 3/23/2022 MT Newswires

Cue Biopharma (CUE) has an average rating of buy and price targets ranging from $15 to $30, according to analysts polled by Capital IQ. (MT Newswires...

View all Commentary and Analysis

Cue Biopharma: A First Assessment
10:25AM ET 5/11/2022 Seeking Alpha

Cue Biopharma: Too Long To Arrive At Topline Trial Data
3:32PM ET 2/23/2022 Seeking Alpha

Medicenna Therapeutics: Treating Cancer With Immunomodulators
9:34PM ET 11/12/2021 Seeking Alpha

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2021 Results - Earnings Call Transcript
9:40PM ET 8/17/2021 Seeking Alpha

Company Profile

Business DescriptionCue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA. View company web site for more details
Address40 Guest Street
Boston, Massachusetts 02135
Number of Employees46
Recent SEC Filing05/10/202210-Q
Chief Executive Officer & DirectorDaniel R. Passeri
President & Chief Scientific OfficerAnish Suri
Chief Financial & Accounting OfficerKerri-Ann Millar
Senior Scientific AdvisorRonald D. Seidel

Company Highlights

Price Open$3.86
Previous Close$3.62
52 Week Range$3.30 - 18.42
Market Capitalization$132.6 M
Shares Outstanding35.4 M
SectorHealth Technology
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.41
Beta vs. S&P 500N/A
Revenue$1.1 M
Net Profit Margin-295.56%
Return on Equity-65.04%

Analyst Ratings as of 05/11/2022

Consensus RecommendationConsensus Icon
Powered by Factset